Hi Readers,

It’s Power Hour, and NanoViricides, Inc. (NYSE American: NNVC) is having an incredible day! Hovering around $2.00 for most of the day, NNVC has surged over 20%. The excitement is continuing as we head into the final stretch of trading. Will NNVC finish as strong as it opened, or even stronger? (2)

This is a company you need to watch closely RIGHT NOW!
 

Why NanoViricides Stands Out
 

NanoViricides, Inc. is at the cutting edge of nano-biopharmaceuticals, discovering, developing, and commercializing drugs to combat some of the world’s most challenging viral infections.
 

✨ Significant Upside Potential: Analysts predict an almost 300% upside with a price target of $6.50, positioning NanoViricides as a standout performer. (2)(5)

(2)

🔬 Innovative Products: Their lead drug candidate, NV-387, is in phase 1a/1b clinical trials for treating C0\/ID-19 and other severe viral infections. Their product portfolio includes oral syrups, gummies, and solutions for various delivery methods, addressing severe cases and pediatric needs.(1)(6)(8)
 

🏆 Industry-Leading Leadership: Led by a team of visionary leaders, NanoViricides is consistently pushing the envelope, driving significant progress and strategic advancements. The company is constantly advancing while being financially savvy .(2)(8)
 

💪 Strong Financials: NanoViricides has consistently exceeded earnings estimates each quarter, demonstrating robust financial health and strategic growth. Just take a look at their Year-to-date return and 1-Year return: (2)(5)

(4)(2)

(4)(2)

🌟 Latest Achievements: Recently, NanoViricides reported that NV-387 showed an ideal flat blood concentration profile, enabling sustained antiviral effects with infrequent dosing. This breakthrough positions NV-387 as a potential game-changer in treating multiple viral infections. (1)(6)(7)
 

📊 Strong Technicals: The company shows strong technical indicators and is poised for a breakout, making it a compelling choice for savvy researchers. (4)

(4)

NanoViricides, Inc. (NYSE American: NNVC) is not just another biopharma company; it’s a pioneer in its field. With their cutting-edge nanotechnology and a robust pipeline of treatments, they are well-positioned to make a significant impact in the healthcare industry. 

The company’s innovative approach and relentless drive for excellence make it a true leader.
 

Stay tuned for more exciting updates as NanoViricides, Inc. (NYSE American: NNVC) continues to push the boundaries of biopharmaceutical innovation.
 

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources: 
1. https://finance.yahoo.com/news/orally-administered-nv-387-results-103000671.html
2. https://finance.yahoo.com/quote/NNVC/
3. https://finance.yahoo.com/quote/NNVC/history/
4. https://bit.ly/3VPJfLb
5. https://on.mktw.net/4c9Brtd
6. https://finance.yahoo.com/news/sustained-slow-declining-blood-concentration-103000058.html
7.https://finance.yahoo.com/news/nanoviricides-filed-quarterly-report-103000942.html
8. https://www.nanoviricides.com/
9. https://finance.yahoo.com/news/novel-broad-spectrum-antiviral-against-103000636.html

Data is provided from third-party sources and Market Tips is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc.laim.er here. 

Pursuant to an agreement between Momentum Media LLC and Sica Media LLC, Momentum Media LLC has been hired for a period beginning on 06/19/2024 and ending on 06/20/2024 to publicly disseminate information about (NNVC:US) via digital communications. We have been paid an additional ten thousand dollars USD. To date we have been paid thirty three thousand dollars USD. We own zero shares of (NNVC:US).